ZoomRx Wants to Stop Pharma From Paying Twice for the Same Answer

For years, a pharma study ended with a deck and a folder. ZoomRx is betting that its 60,000-plus-member panel, 700 million benchmark data points and new AI products can turn those forgotten files into a living commercial memory.